您当前的位置：
首页 >
文章列表页 >
Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives
Review | 更新时间：2026-02-09

    • Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

    • “This paper introduced the research progress of CENPA in the field of breast cancer, and experts revealed its expression characteristics and key regulatory mechanisms in different molecular types, providing a new idea for precision treatment of breast cancer.”
    • China Oncology   Vol. 35, Issue 12, Pages: 1148-1153(2025)

    • DOI：10.19401/j.cnki.1007-3639.2025.12.007    

      CLC： R737.9

    • Received：11 April 2025，

      Revised：2025-08-12，

      Published：30 December 2025

    移动端阅览

  • LU Ye, ZHANG Wenxiang, KONG Xiangyi, et al. Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives[J]. China Oncology, 2025, 35(12): 1148-1153. DOI： 10.19401/j.cnki.1007-3639.2025.12.007.

  •  
  •  

0

Views

5

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Current status and future perspectives of antibody-drug conjugates in breast cancer therapy
Research advances in estrogen receptor low positive early breast cancer
Progress of important clinical trials of breast cancer in China in 2022
GRM4 positive allosteric modulators inhibit breast cancer cell proliferation and promote cell apoptosis
Progress and future directions of important clinical research on breast cancer in China in 2025

Related Author

Jialin LIN
Wenna WANG
Binghe XU
Yizi JIN
Mingxi LIN
Cheng ZENG
Qing GUO
Jian ZHANG

Related Institution

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Medical Oncology, Fudan University Shanghai Cancer Center; Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Collaborative Innovation Center for Cancer Medicine, Fudan University
中国人民解放军广州总医院检验科
0